Physician profile
Clayton A Everline
NPI 1346408820
$2,028.60
in general payments reported to CMS, 2019-2025
11 companies · $889 in 2025
The $889 reported for 2025 was more than what 92% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $123 · 2022: $381 · 2023: $52.13 · 2024: $393 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.03 | 2022-2025 | |
| Novo Nordisk INC | $258.12 | 2025 | Ozempic, Wegovy |
| Electronic Waveform Lab, INC. | $252.44 | 2024 | |
| Amgen INC. | $193.87 | 2025 | Tepezza, Krystexxa |
| Team_makena_llc | $190.40 | 2019 | |
| Abbott Laboratories | $159.09 | 2025 | Proclaim |
| Boston Scientific Corporation | $140.32 | 2025 | General - Pain Management |
| Kowa Pharmaceuticals America, INC. | $124.71 | 2022 | |
| Eisai INC. | $123.35 | 2020 | |
| Nevro Corp. | $91.99 | 2022 | |
| Pfizer INC. | $50.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Everline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.